Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosopt Effects on ODPP in Glaucoma
NCT00796198Phase 4
Key facts
- Status
- Unknown
- Start
- Dec 2008
- Primary completion
- Jun 2009
- Countries
- 1
- Sponsor
- University of Turin
- Modality
- Small Molecules
- Drugs
- dorzolamide
- Conditions
- primary open-angle glaucoma (POAG)
01
Overview
Phase 4, open-label trial of dorzolamide in primary open-angle glaucoma (POAG) (2 arms), sponsored by University of Turin. Primary endpoint: Ocular Diastolic Perfusion Pressure at 3 months. Status: unknown.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Add Group
Patients not controlled on Xalatan receive add-on Cosopt.
Control Group
Patients controlled on Xalatan continue monotherapy.
03
Who it enrols
Patients with POAG aged 45-65 treated with Xalatan. Inclusion requires early/mid-stage glaucoma (pattern deviation 2.5-6.0 dB). Exclusion includes normal tension glaucoma, ocular hypertension, diabetes, and use of systemic beta-blockers.
04
Endpoints
Primary
Ocular Diastolic Perfusion Pressure
Secondary
Intraocular Pressure
Beyond the preview
Go deeper on NCT00796198.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796198.